Abstract
Rationale
One assumption of Schild analyses, which have been used extensively to characterize opioids in vitro and in vivo, is that the concentration of antagonist is at equilibrium; violation of this assumption would yield slopes of Schild plots that deviate from unity. For in vivo studies, the concentration of antagonist changes as it is eliminated; however, if studies are conducted at a time when the antagonist is maximally effective, the assumption of equilibrium is not violated.
Objective
The goal of these studies was to determine how increasing the delay between antagonist administration and determination of dose–effect curves alters results of Schild analyses.
Materials and methods
Monkeys received 3.2 mg/kg/day of morphine and discriminated naltrexone while responding under a fixed-ratio 5 schedule of stimulus-shock termination. In monkeys acutely deprived of morphine (27 h), naltrexone was administered 1, 2, 4, or 6 h before determination of morphine dose–effect curves.
Results
Morphine-deprived monkeys responded on the naltrexone-appropriate lever, and this effect was reversed by morphine. Naltrexone dose- and time-dependently antagonized morphine. Schild analyses yielded slopes that did not deviate from unity; however, as the delay between naltrexone administration and determination of morphine dose–effect curves increased, apparent pA2 values decreased.
Conclusions
The assumption of equilibrium of antagonist at receptor sites does not appear to be violated, regardless of when it is administered, and changes in naltrexone concentration as it is eliminated are reflected in orderly decreases in potency. These results further indicate the strength of Schild analyses for describing interactions between drugs and receptors in vivo.
Similar content being viewed by others
References
Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48–58
Bertalmio AJ, Woods JH (1987) Differentiation between mu and kappa receptor-mediated effects in opioid drug discrimination: apparent pA2 analysis. J Pharmacol Exp Ther 243:591–597
Brandt MR, Cabansag SR, France CP (1997) Discriminative stimulus effects of l-α-acetylmethadol (LAAM), buprenorphine and methadone in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 282:574–584
Dykstra LA, Gmerek DE, Winger G, Woods JH (1987) Kappa opioids in rhesus monkeys. II. Analysis of antagonistic actions of quadazocine and beta-funaltrexamine. J Pharmacol Exp Ther 242:421–437
Dykstra LA, Bertalmio AJ, Woods JH (1988) Discriminative and analgesic effects of mu and kappa opioids: in vivo pA2 analysis. Psychopharmacol Ser 4:107–121
France CP, Gerak LR (1994) Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys. J Pharmacol Exp Ther 270:992–999
France CP, Woods JH (1989) Discriminative stimulus effects of naltrexone in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 250:937–943
France CP, de Costa BR, Jacobson AE, Rice KC, Woods JH (1990) Apparent affinity of opioid antagonists in morphine-treated rhesus monkeys discriminating between saline and naltrexone. J Pharmacol Exp Ther 252:600–604
Gerak LR, Butelman ER, Woods JH, France CP (1994) Antinociceptive and respiratory effects of nalbuphine in rhesus monkeys. J Pharmacol Exp Ther 271:993–999
Gerak LR, Gauthier CA, France CP (2003) Discriminative stimulus and antinociceptive effects of dihydroetorphine in rhesus monkeys. J Pharmacol Exp Ther 166:351–359
Kenakin T (1993) Pharmacologic analysis of drug-receptor interaction (2nd ed). Raven, New York
Koek W, Assié MB, Zernig G, France CP (2000) In vivo estimates of efficacy at 5-HT1A receptors: effects of EEDQ on the ability of agonists to produce lower-lip retraction in rats. Psychopharmacol 149:377–387
Negus SS, Burke TF, Medzihradsky F, Woods JH (1993) Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine. J Pharmacol Exp Ther 267:896–903
Takemori AE, Portoghese PS (1984) Comparative antagonism by naltrexone and naloxone of μ, κ and δ agonists. Eur J Pharmacol 104:101–104
Walker EA, Butelman ER, DeCosta BR, Woods JH (1993) Opioid thermal antinociception in rhesus monkeys: receptor mechanisms and temperature dependency. J Pharmacol Exp Ther 267:280–286
Walker EA, Makhay MM, House JD, Young AM (1994) In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats. J Pharmacol Exp Ther 271:959–968
Acknowledgments
The authors wish to thank R. Gump and S. Wegert for their excellent technical assistance and Dr. Wouter Koek for his help with data analyses. Monkeys used in these studies were maintained in accordance with the Institutional Animal Care and Use Committee, Louisiana State University Health Sciences Center, and guidelines of the Committee on Care and Use of Laboratory Animal Resources, National Research Council (Department of Health, Education and Welfare, publication No. (NIH) 85-23, revised 1996). These studies were supported by United States Public Health Service Grant DA05018 and Senior Scientist Award K05 DA17918 (CPF).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gerak, L.R., France, C.P. Time-dependent decreases in apparent pA2 values for naltrexone studied in combination with morphine in rhesus monkeys. Psychopharmacology 193, 315–321 (2007). https://doi.org/10.1007/s00213-007-0787-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-007-0787-y